Generic Name and Formulations:
Lixisenatide 50mcg/mL, 100mcg/mL; soln for SC inj; contains m-cresol.
Indications for ADLYXIN:
As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.
Limitations Of use:
Not studied in patients with history of unexplained pancreatitis; consider other antidiabetics. Not a substitute for insulin. Not for treating type 1 diabetes or ketoacidosis. Not recommended with concurrent short-acting insulin. Not recommended in gastroparesis.
Give by SC inj once daily within the hour prior to first meal into abdomen, thigh, or upper arm; rotate inj sites. ≥18yrs: Initially 10mcg once daily for 14 days, then 20mcg once daily.
<18yrs: not established.
Do not reuse or share pens, needles, or syringes between patients. Discontinue if hypersensitivity reaction occurs. Monitor for signs/symptoms of pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis: consider alternative antidiabetics. Renal impairment or severe GI reactions: monitor when initiating or escalating doses. ESRD: not recommended. Pregnancy. Nursing mothers.
Increased risk of hypoglycemia with concomitant sulfonylureas or basal insulin (reduction in their doses may be needed). May affect absorption of oral drugs (delayed gastric emptying). Caution when concomitant oral drugs with narrow therapeutic ratio or that require careful monitoring. Concomitant antibiotics, APAP, other drugs dependent on threshold concentration: administer ≥1hr before Adlyxin; for oral contraceptives, take ≥1hr before or 11hrs after Adlyxin.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Nausea, vomiting, headache, diarrhea, dizziness, hypoglycemia, inj site reactions, allergic reactions; pancreatitis, renal failure, possibly antibody formation.
Starter pack—2 prefilled pens (10mcg + 20mcg); Maintenance pack—2 prefilled pens (20mcg)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|